Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked
monoclonal antibody (an antibody-drug conjugate) that was used to treat acute ...
This page contains brief information about gemtuzumab ozogamicin and a
collection of links to more information about the use of this drug, research results,
Mylotarg is the trade name for gemtuzumab ozogamicin. In some cases, health
care professionals may use the trade name mylotarg when referring to the ...
Information about the monoclonal antibody gemtuzumab (Mylotarg®), which is
mainly used as part of research trials to treat some types of acute myeloid ...
Jun 21, 2010 ... BACKGROUND: Mylotarg (gemtuzumab ozogamicin), indicated for treatment of
acute myeloid leukemia (AML), a bone marrow cancer, was ...
Nov 10, 2012 ... On May 17, 2000, the US Food and Drug Administration (FDA) granted
accelerated approval for the use of gemtuzumab ozogamicin (GO) in ...
Jun 13, 2013 ... Gemtuzumab ozogamicin (GO) consists of a humanized anti-CD33 monoclonal
antibody conjugated with calicheamicin, a potent antitumor ...
Easy to read patient leaflet for gemtuzumab ozogamicin. Includes indications,
proper use, special instructions, precautions, and possible side effects.
Bioconjug Chem. 2002 Jan-Feb;13(1):47-58. Gemtuzumab ozogamicin, a potent
and selective anti-CD33 antibody-calicheamicin conjugate for treatment of ...
PURPOSE: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories,
Philadelphia, PA) consists of a semisynthetic derivative of calicheamicin, a